Bronchoscopy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bronchoscopy is a minimally invasive medical procedure in which a physician — typically a pulmonologist (respiratory specialist) or thoracic surgeon — passes a thin, fibre-optic or video bronchoscope through the nose or mouth, past the vocal cords, and into the trachea and bronchial tree (airways of the lungs) to directly visualise the airway lining, identify abnormalities, collect biological samples, or perform therapeutic interventions. It is one of the most important and versatile diagnostic and therapeutic tools in pulmonology.

Flexible bronchoscopy (the most commonly performed form) uses a 4 to 6 mm diameter flexible video bronchoscope under conscious sedation with topical local anaesthetic. The procedure takes 15 to 45 minutes as a day case. The bronchoscopist visualises the trachea, right and left main bronchi, lobar and segmental bronchi in high definition, identifying mucosal abnormalities, tumours, strictures, foreign bodies, or bleeding sources. Through the working channel of the scope, biopsy forceps, cytology brushes, needles, and lavage catheters are passed to collect samples.

Rigid bronchoscopy uses a larger metal tube through which general anaesthesia is administered, allowing the passage of larger instruments, better control of massive haemoptysis, and performance of advanced therapeutic procedures including stent placement, laser ablation, and foreign body retrieval under general anaesthesia. Endobronchial ultrasound (EBUS) bronchoscopy adds real-time ultrasound imaging at the scope tip, enabling guided needle aspiration of mediastinal and hilar lymph nodes — a transformative innovation in lung cancer staging.

Bronchoscopy is indicated for the investigation and management of numerous pulmonary conditions. Haemoptysis (coughing up blood) requires bronchoscopic evaluation to identify the source of bleeding, which may be a bronchial tumour, bronchiectasis, arteriovenous malformation, or simple endobronchial infection. Abnormal chest CT findings including pulmonary masses, nodules, consolidation, or mediastinal lymphadenopathy require bronchoscopic biopsy for tissue diagnosis. Suspected or confirmed lung cancer is the single most common indication — central tumours are directly visible and biopsied; peripheral lesions are sampled by navigational or fluoroscopic-guided techniques.

Infectious causes of pneumonia in immunocompromised patients (transplant recipients, chemotherapy patients, HIV-positive individuals) require bronchoalveolar lavage (BAL) for microbiological diagnosis including bacterial, fungal, and viral cultures. Diffuse interstitial lung diseases (idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis) are biopsied via transbronchial forceps biopsy or cryobiopsy. Vocal cord abnormalities, tracheal stenosis, and suspected foreign body aspiration are directly assessed and managed bronchoscopically. In critically ill ventilated patients, therapeutic bronchoscopy removes mucus plugs causing lobar collapse.

Most adult patients with clinical or radiological findings requiring airway investigation are candidates for flexible bronchoscopy. Patients should be haemodynamically stable and able to tolerate mild conscious sedation. Supplemental oxygen can be provided throughout the procedure, allowing patients with moderate hypoxaemia to proceed safely. Pre-bronchoscopy blood tests include full blood count, clotting screen (INR must typically be below 1.5 for biopsy procedures), and renal function (for medication dosing). Patients on anticoagulants require periprocedural management per institutional protocols.

Contraindications to elective bronchoscopy include severe refractory hypoxaemia not correctable with supplemental oxygen, unstable cardiac arrhythmias, recent myocardial infarction (within four weeks), uncorrectable coagulopathy for biopsy procedures, and patient refusal. Emergency bronchoscopy for life-threatening indications (massive haemoptysis, foreign body causing severe obstruction) proceeds regardless of relative medical risks as the alternative is death or severe respiratory failure. Patients with severe COPD or pulmonary fibrosis may have reduced functional reserve, requiring careful pre-procedure assessment of oxygen requirements.

Standard flexible bronchoscopy with direct visualisation, forceps biopsy, brushings, and BAL is performed for most diagnostic indications. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) uses a dedicated EBUS bronchoscope to image mediastinal lymph nodes in real time and aspirate samples with a 22-gauge needle — this is now the standard of care for lung cancer nodal staging, with sensitivity exceeding 90% and specificity approaching 100% at experienced centres, replacing surgical mediastinoscopy in most cases.

Transbronchial lung biopsy (TBLB) using fluoroscopic guidance allows sampling of peripheral parenchymal lesions and diffuse infiltrates. Transbronchial cryobiopsy uses liquid nitrogen or CO2 to freeze and retrieve larger specimens (5 to 8 mm vs 1 to 3 mm with forceps) with superior histological preservation, significantly improving diagnostic yield for interstitial lung diseases. Navigational bronchoscopy systems (electromagnetic navigation, CT-fluoroscopic fusion, robotic bronchoscopy platforms) guide the bronchoscope to peripheral nodules as small as 8 to 10 mm in diameter — important for earlier diagnosis of peripherally located lung cancers. Therapeutic procedures including endobronchial valve placement for emphysema treatment, airway stenting, and thermoplasty for severe refractory asthma are performed via bronchoscopy. Robotic bronchoscopy systems (Ion, Monarch) provide enhanced navigation to peripheral pulmonary lesions below 2 cm in diameter, achieving diagnostic yields of 70–80% with a favourable safety profile. Airway stenting with silicone or metallic stents, intraluminal laser or argon plasma coagulation for tumour debulking, and thermoplasty for severe refractory asthma are performed via bronchoscopy.

Flexible bronchoscopy provides direct real-time visualisation of the airways that cannot be replicated by any imaging modality, enabling biopsy of visible endobronchial lesions with diagnostic sensitivity of 80 to 90% for central lung tumours. EBUS bronchoscopy has dramatically improved lung cancer staging, achieving sensitivity of 90 to 95% for malignant mediastinal lymphadenopathy as a day-case procedure under conscious sedation, compared with mediastinoscopy which requires general anaesthesia and a surgical incision with overnight hospitalisation.

Therapeutic bronchoscopy saves lives in critical care by clearing airway secretions in ventilated patients, successfully retrieves foreign bodies (including coins, nuts, teeth, and toy parts) in over 95% of cases without the need for thoracic surgery, and provides valuable palliative benefit for patients with advanced thoracic malignancy through airway stenting and laser debulking. The diagnostic information from bronchoscopy — particularly molecular profiling of lung cancer biopsies — directly guides treatment selection including targeted therapies and immunotherapy.

Flexible bronchoscopy has a major complication rate of less than 0.5% in prospective series at specialist centres. Common minor complications include transient fever within 24 hours of BAL (self-limiting), mild transient haemoptysis after forceps biopsy (almost universally self-limiting with cold saline lavage), and bronchospasm requiring nebulised bronchodilators. Oxygen desaturation during the procedure is common and managed with supplemental oxygen adjustment.

Pneumothorax after transbronchial biopsy occurs in approximately 1 to 6% of biopsies — the majority are small and resolve spontaneously, with only 1 to 2% requiring chest drain insertion. Clinically significant haemorrhage after biopsy occurs in less than 1% of cases and is managed with topical adrenaline, cold saline, bronchial blocking, or tamponade. Systemic lidocaine toxicity from topical airway application is uncommon but can cause seizures if dose limits (7 mg/kg) are exceeded. Sedation-related complications including aspiration, respiratory depression, and paradoxical agitation occur in less than 0.5% of cases with standard monitoring and appropriately trained staff.

After bronchoscopy, patients recover in a monitored area for one to two hours. Continuous pulse oximetry and observation until fully alert and orientated are standard. Patients must not eat or drink until the topical airway anaesthesia has worn off and normal swallowing has returned — typically 60 to 90 minutes after the scope is removed. A small amount of blood-tinged sputum and mild sore throat or hoarseness are normal for 24 to 48 hours. Patients must not drive for 24 hours after sedation and should be accompanied home.

Chest X-ray is performed before discharge after transbronchial biopsy to exclude pneumothorax. Written instructions about warning signs (increasing breathlessness, chest pain, significant haemoptysis, fever) requiring emergency attention are provided. Results from BAL cultures are available within 48 to 96 hours; biopsy histopathology takes 3 to 7 days. The bronchoscopist or referring physician arranges a follow-up appointment or phone consultation to discuss results and plan management, particularly important when malignancy is suspected.

In the United States, flexible bronchoscopy with sedation and basic sampling costs $2,000 to $6,000 in an outpatient setting. EBUS bronchoscopy with mediastinal sampling and appropriate molecular testing costs $5,000 to $12,000. These costs are typically covered by health insurance for medically indicated procedures. In the UK, NHS bronchoscopy is performed free of charge with typical wait times of two to four weeks for non-urgent indications.

At accredited respiratory centres in India and Thailand, flexible bronchoscopy including sedation and sampling costs $300 to $800, and EBUS bronchoscopy is $600 to $1,500 — representing savings of 75 to 85% versus US rates. Importantly, molecular profiling of lung cancer biopsies (EGFR, ALK, ROS1, KRAS, PD-L1) at accredited pathology laboratories in these centres is performed to international standards, allowing the results to be used for treatment decisions by oncologists worldwide. International patients should explicitly request comprehensive molecular testing at the time of biopsy.

CT-guided percutaneous needle biopsy is the principal alternative for peripheral pulmonary lesions, achieving diagnostic accuracy of 85 to 95% for solid masses but with higher pneumothorax rates (15 to 25%) than bronchoscopy and unsuitability for mediastinal lesions. Surgical biopsy via VATS (video-assisted thoracoscopic surgery) provides the largest tissue samples and is definitive when less invasive procedures fail or when excision rather than sampling is required. Liquid biopsy (plasma circulating tumour DNA) is an emerging complementary tool in lung cancer that can detect driver mutations and resistance mutations but is not a substitute for tissue biopsy for initial diagnosis and PD-L1 testing.

For microbiological diagnosis of pneumonia in immunocompromised patients, induced sputum (hypertonic saline nebulisation) provides a non-bronchoscopic option for Pneumocystis jirovecii (PCP) and some bacterial and fungal pathogens, with sensitivity of 70 to 80% compared with BAL sensitivity of 90 to 98%. Serum biomarkers (Aspergillus galactomannan, beta-D-glucan) can support diagnosis of fungal pneumonia without bronchoscopy in some clinical contexts.